ReviewImmunological reviews2016
Endosomal Toll-like receptors in clinically overt and silent autoimmunity.
Review in Immunological reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- The emerging clinical relevance of cell-free DNA in lupus: from mechanistic insights to therapeutic opportunities.Frontiers in immunology · 2026Review
- Role of combination immunotherapy in restoring brain synergistic functional connectivity in patients with systemic lupus erythematosus without overt neuropsychiatric manifestations.Lupus science & medicine · 2025Article
- The toll like receptor 7 pathway and the sex bias of systemic lupus erythematosus.Frontiers in immunology · 2025Article
- From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases.Frontiers in immunology · 2025Review
- Targeting toll-like receptor 7 as a therapeutic development strategy for systemic lupus erythematosus.Acta pharmaceutica Sinica. B · 2024Article
- MiR-574-5p activates human TLR8 to promote autoimmune signaling and lupus.Cell communication and signaling : CCS · 2024Article
- Toll-like receptors 7 and 9 regulate the proliferation and differentiation of B cells in systemic lupus erythematosus.Frontiers in immunology · 2023Review
- Calcium/calmodulin-dependent protein kinase IV promotes imiquimod-induced psoriatic inflammation via macrophages and keratinocytes in mice.Nature communications · 2022Article
- 47XXY and 47XXX in Scleroderma and Myositis.ACR open rheumatology · 2022Article
- Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Biomarkers in the Light of the Etiopathology of IC/BPS.Diagnostics (Basel, Switzerland) · 2021Review
- Variety of endosomal TLRs and Interferons (IFN-α, IFN-β, IFN-γ) expression profiles in patients with SLE, SSc and MCTD.Clinical and experimental immunology · 2021Article
- Hydroxychloroquine Inhibits Macrophage Activation and Attenuates Renal Fibrosis After Ischemia-Reperfusion Injury.Frontiers in immunology · 2021Article
- Baicalein ameliorates pristane-induced lupus nephritis via activating Nrf2/HO-1 in myeloid-derived suppressor cells.Arthritis research & therapy · 2019Article
- Association of toll-like receptor 9 expression with prognosis of systemic lupus erythematosus.Experimental and therapeutic medicine · 2019Article
- Dual Toll-Like Receptor Targeting Liposomal Spherical Nucleic Acids.Bioconjugate chemistry · 2019Article
- Cross-Disease Innate Gene Signature: Emerging Diversity and Abundance in RA Comparing to SLE and SSc.Journal of immunology research · 2019Article
- Lysosomal pH Is Regulated in a Sex Dependent Manner in Immune Cells ExpressingFrontiers in immunology · 2019Article
- Siglec-1 Macrophages and the Contribution of IFN to the Development of Autoimmune Congenital Heart Block.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans?Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Toll-like receptors (TLRs), first identified as pattern recognition receptors, are now recognized to serve as a key interface between innate and adaptive immunity. Systemic lupus erythematosus (SLE) is characterized by both continuous and cyclic stimulation of the innate and adaptive immune system by endogenous nucleic acids released from apoptotic or necrotic cells. TLR7 and TLR9 function as innate sensors of viral infection as their ligands are ssRNA and dsDNA, respectively. Recognition of self nucleic acids by endosomal TLRs in B cells and pDCs is thought to be an important step in the pathogenesis of SLE, generating anti-nuclear antibodies and producing type I IFN. In this review, we take a specific look at how TLR7, non-coding RNA, and SSA/Ro60 can contribute to clinical autoimmunity and organ damage in the context of neonatal lupus (NL). Although 15 times less common than SLE, NL provides a unique opportunity to study two different aspects of autoimmunity: passively acquired tissue injury in a developing fetus and clinical progression of disease in an asymptomatic mother found to have anti-Ro60 autoantibodies only after identification of heart block/rash in a child. Finally, we discuss hydroxychloroquine (HCQ) use by asymptomatic subjects which may forestall the clinical expression of autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.